p.76 抽出テキスト

CLINICAL STATEMENTS AND GUIDELINES

June 11, 2024 Circulation. 2024;149:e1313–e1410. DOI: 10.1161/CIR.0000000000001251 e1388

25.	 Selvarajah S, Black JH 3rd, Malas MB, et al. Preoperative smoking is associated with early graft failure after infrainguinal bypass surgery. J Vasc Surg. 2014;59:1308–1314. 26.	 Ekezie W, Murray RL, Agrawal S, et al. Quality of smoking cessation advice in guidelines of tobacco-related diseases: an updated systematic review. Clin Med (Lond). 2020;20:551–559. 27.	 Tonstad S, Lawrence D. Varenicline in smokers with diabetes: a pooled analysis of 15 randomized, placebo-controlled studies of varenicline. J Diabetes Investig. 2017;8:93–100. 28.	 West R. Tobacco smoking: health impact, prevalence, correlates and interventions. Psychol Health. 2017;32:1018–1036. 29.	 Malas M, van der Tempel J, Schwartz R, et al. Electronic cigarettes for smoking cessation: a systematic review. Nicotine Tob Res. 2016;18:1926–1936. 30.	 Hartmann-Boyce J, McRobbie H, Lindson N, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2020;10:CD010216. 31.	 Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019;380:629–637. 32.	 Patel KK, Jones PG, Ellerbeck EF, et al. Underutilization of evidence-based smoking cessation support strategies despite high smoking addiction burden in peripheral artery disease specialty care: insights from the international PORTRAIT registry. J Am Heart Assoc. 2018;7:e010076. 33.	 Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC Expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2018;72:3332–3365. 34.	 Schober W, Fembacher L, Frenzen A, et al. Passive exposure to pollutants from conventional cigarettes and new electronic smoking devices (IQOS, ecigarette) in passenger cars. Int J Hyg Environ Health. 2019;222:486–493. 35.	 Tan CE, Glantz SA. Association between smoke-free legislation and hos-

pitalizations for cardiac, cerebrovascular, and respiratory diseases: a metaanalysis. Circulation. 2012;126:2177–2183. 5.5. Diabetes Management for PAD 1.	 Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322. 2.	 Cosmi F, Laini R, Nicolucci A. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2017;376:890. 3.	 Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257. 4.	 Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–130. 5.	 Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–1239. 6.	 Verma S, Al-Omran M, Leiter LA, et al. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022;24:1288–1299. 7.	 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117– 2128. 8.	 Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357. 9.	 Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–1435. 10.	 Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657. 11.	 Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306. 12.	 Heyward J, Mansour O, Olson L, et al. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis. PLoS One. 2020;15:e0234065. 13.	 Lane KL, Abusamaan MS, Voss BF, et al. Glycemic control and diabetic foot ulcer outcomes: a systematic review and meta-analysis of observational studies. J Diabetes Complications. 2020;34:107638. 14.	 Takahara M, Kaneto H, Iida O, et al. The influence of glycemic control on the prognosis of Japanese patients undergoing percutaneous transluminal angioplasty for critical limb ischemia. Diabetes Care. 2010;33:2538–2542. 15.	 Singh S, Armstrong EJ, Sherif W, et al. Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty. Vasc Med. 2014;19:307–314. 16.	 Arya S, Binney ZO, Khakharia A, et al. High hemoglobin A(1c) associated

with increased adverse limb events in peripheral arterial disease patients undergoing revascularization. J Vasc Surg. 2018;67:217–228.e1. 17 ElSayed NA, Aleppo G, Aroda VR, et al. Introduction and methodology: stan-

dards of care in diabetes-2023. Diabetes Care. 2023;46:S1-S4. 18.	 Low Wang CC, Blomster JI, Heizer G, et al. Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. J Am Coll Cardiol. 2018;72:3274–3284. 19.	 Resnick HE, Carter EA, Sosenko JM, et al. Incidence of lower-extremity amputation in American Indians: the Strong Heart Study. Diabetes Care. 2004;27:1885–1891. 20.	 Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024;267:1–11. 21.	 US Food and Drug Administration. FDA removes boxed warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). 2020. Accessed March 1, 2021. https:// www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin. 22.	 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–e1032. 23.	 Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509–1526. 24.	 Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47:921–929. 25.	 Jude EB, Oyibo SO, Chalmers N, et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001;24:1433–1437. 26.	 Su JB, Zhao LH, Zhang XL, et al. HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients. Cardiovasc Diabetol. 2018;17:47. 27.	 American Diabetes Association. 11. Microvascular complications and

foot care: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S124-S138. 5.6. Other Medical Therapies for Cardiovascular Risk Reduction in PAD 1.	 Davis MM, Taubert K, Benin AL, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. Circulation. 2006;114:1549–1553. 2.	 Gurfinkel EP, Leon de la Fuente R, Mendiz O, et al. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J. 2004;25:25–31. 3.	 Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J. 2008;29:1350–1358. 4.	 Phrommintikul A, Kuanprasert S, Wongcharoen W, et al. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011;32:1730–1735. 5.	 Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310:1711–1720. 6.	 Fontana L. Interventions to promote cardiometabolic health and slow cardiovascular ageing. Nat Rev Cardiol. 2018;15:566–577. 7.	 Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596–e646. 8.	 Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117–1124. 9.	 Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885–888. 10.	 Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378:e34. 11.	 Ruiz-Canela M, Estruch R, Corella D, et al. Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial. JAMA. 2014;311:415–417. 12.	 Martinez-Gonzalez MA, Sanchez-Tainta A, Corella D, et al. A provegetar-

ian food pattern and reduction in total mortality in the Prevencion con Dieta Mediterranea (PREDIMED) study. Am J Clin Nutr. 2014;100(Suppl 1):320S-328S.

Downloaded from http://ahajournals.org by on October 7, 2026